NASDAQ:VRDN

Viridian Therapeutics News Headlines

$13.52

+2.96 (+28.03%)

(As of 05/13/2022 06:55 PM ET)

Add

Compare

Today's Range: $10.75
▼
$14.16
50-Day Range: $9.55
▼
$20.44
52-Week Range: $9.47
▼
$22.00

Volume: 500,900 shs
Average Volume: 135,438 shs
Market Capitalization: $367.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 1.12

Get Viridian Therapeutics News Delivered to You Automatically

Media Mentions By Week

Viridian Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VRDN
News Sentiment
▼
-0.29

0.48
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VRDN Articles
This Week
▼
11

1
▲
VRDN Articles
Average Week

Viridian Therapeutics (NASDAQ:VRDN) News Headlines Today

Source

Source	Headline
	Viridian Therapeutics Shares Soar 32% Following Drug Trial Updates, 1Q Results marketwatch.com - May 13 at 4:10 PM
	Viridian Therapeutics: Q1 Earnings Insights benzinga.com - May 13 at 1:39 AM
	Viridian Therapeutics GAAP EPS of $0.98, revenue of $0.22M seekingalpha.com - May 13 at 1:39 AM
	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates nasdaq.com - May 13 at 1:39 AM
	Viridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - May 13 at 1:39 AM
	Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates finance.yahoo.com - May 13 at 1:39 AM
	Jonathan Violin Sells 30,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock americanbankingnews.com - May 6 at 5:08 AM
	Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022 finance.yahoo.com - May 3 at 10:26 AM
	Reviewing Viridian Therapeutics (NASDAQ:VRDN) & Sera Prognostics (NASDAQ:SERA) americanbankingnews.com - April 23 at 1:46 AM
	Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14 finance.yahoo.com - April 6 at 12:35 PM
	Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease finance.yahoo.com - March 21 at 5:52 PM

	Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15 finance.yahoo.com - March 14 at 7:31 PM
	Oppenheimer Bets on These 2 Stocks; Sees Over 40% Upside Potential finance.yahoo.com - March 14 at 7:31 PM
	Viridian Therapeutics GAAP EPS of -$1.32, revenue of $0.21M seekingalpha.com - March 12 at 2:39 AM
	Viridian Therapeutics: Q4 Earnings Insights benzinga.com - March 10 at 7:59 PM
	Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates finance.yahoo.com - March 10 at 7:59 PM
	Strong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of five-year loss finance.yahoo.com - March 10 at 2:56 PM
	Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022 finance.yahoo.com - March 3 at 7:57 PM
	Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates nasdaq.com - February 28 at 10:13 PM
	Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18 finance.yahoo.com - February 14 at 9:49 AM
	Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease markets.businessinsider.com - January 31 at 2:56 PM
	Viridian wins FDA OK to start clinical trial for thyroid eye disease candidate seekingalpha.com - January 31 at 9:55 AM
	Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease finance.yahoo.com - January 31 at 9:55 AM
	Viridian Therapeutics Submits Investigational New Drug Application For VRDN-002 To FDA benzinga.com - January 4 at 10:32 AM
	Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration finance.yahoo.com - January 4 at 10:32 AM
	Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED) finance.yahoo.com - December 20 at 10:06 AM
	Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED) finance.yahoo.com - December 20 at 10:06 AM
	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - November 30 at 8:50 AM
	Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED) finance.yahoo.com - November 15 at 10:01 AM
	Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 5 at 1:39 AM
	Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates finance.yahoo.com - November 4 at 8:38 PM
	Viridian Therapeutics to Present at Upcoming Investor Conferences finance.yahoo.com - November 3 at 7:52 PM

	BRIEF-Viridian Therapeutics Inc Submits Investigational New Drug Application For VRDN-001 To The U.S. Food And Drug Administration msn.com - October 14 at 8:25 AM
	Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration finance.yahoo.com - October 14 at 8:25 AM
	Viridian Therapeutics, Inc. (VRDN) realmoney.thestreet.com - October 14 at 3:25 AM
	Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association finance.yahoo.com - September 30 at 8:10 AM
	Last Week’s 3 Most Intriguing Insider Buys insidertrades.com - September 30 at 7:00 AM
	Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares finance.yahoo.com - September 23 at 5:25 PM
	Viridian Therapeutics Shares Rise 17% After Public Offering Prices marketwatch.com - September 21 at 11:34 PM
	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock finance.yahoo.com - September 21 at 8:33 AM
	BRIEF-Viridian Therapeutics Announces Proposed Public Offering Of Common Stock And Preferred Stock msn.com - September 20 at 6:58 PM
	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock finance.yahoo.com - September 20 at 6:58 PM
	Strong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of three-year loss finance.yahoo.com - August 23 at 3:38 PM
	Shareholders in Viridian Therapeutics (NASDAQ:VRDN) have lost 87%, as stock drops 15% this past week nasdaq.com - August 12 at 5:32 PM
	Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates finance.yahoo.com - August 11 at 11:33 AM
	Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference finance.yahoo.com - August 5 at 9:43 AM
	Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer finance.yahoo.com - July 26 at 12:31 PM
	Plaza Premium Cuts Ties With Priority Pass. Here’s What It Means For You. sg.finance.yahoo.com - July 15 at 6:16 PM
	Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee finance.yahoo.com - July 15 at 6:16 PM
	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - July 14 at 8:59 AM

Get Viridian Therapeutics News Delivered to You Automatically

This page was last updated on 5/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources